Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 5/20 | 0.74 |
| ▸ | SLC9A2 | Q9UBY0 | 2/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.72 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.72 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.56 |
| ▸ | MALT1 | Q9UDY8 | 9/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7686352 | 0.99 | SLC9A1 (0.74) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL6312530 | 0.92 | SLC9A1 (0.62) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL6669854 | 0.90 | SLC9A1 (0.72) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL6588864 | 0.87 | SLC9A1 (0.68) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL13286332 | 0.85 | SLC9A1 (0.69) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Zoniporide SCHEMBL611159 | 0.85 | SLC9A1 (1.00) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Zoniporide SCHEMBL4461125 | 0.84 | SLC9A1 (0.71) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Zoniporide SCHEMBL30148157 | 0.84 | SLC9A1 (1.00) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Acetonitrile SCHEMBL6686974 | 0.84 | SLC9A1 (0.65) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Zoniporide SCHEMBL6260017 | 0.84 | SLC9A1 (0.98) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1056729-B1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | claimed |
| EP-1456181-A1 | METHODS FOR PREPARING SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | Pfizer Products Inc. (US) | 2004-09-15 | — | — | EP | claimed |
| US-6627643-B2 | Sodium-hydrogen exchanger type 1 (NHE-1) inhibitors of formula I' are useful for the prevention and treatment of myocardial ischemic injury. Myocardial ischemic injury can occur in out-patient in perioperative settings and can lead to sudden | PFIZER INC. | 2003-09-30 | — | — | US | claimed |
| EP-1337508-A1 | PREPARATION OF SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | Pfizer Products Inc. (US) | 2003-08-27 | — | — | EP | claimed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | claimed |
| WO-2003051845-A1 | METHODS FOR PREPARING SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-06-26 | — | — | WO | claimed |
| US-20030119873-A1 | METHODS FOR PREPARING SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | PFIZER INC. | 2003-06-26 | — | — | US | claimed |
| US-6441176-B1 | N-(5-CYCLOPROPYL-1-QUINOLIN-5-YL-1H-PYRAZOLE-4-CARBONYL) -GUANIDINE; REACTING QUINOLIN-5-YL-HYDRAZINE AND METHYL-3-CYCLOPROPYL-2-DIMETHYLENAMINO-3-OXOPROPANOATE, HYDROYLZING, FORMING ACYLHALIDE AND FURTHER REACTING WITH GUANIDINE | PFIZER INC. | 2002-08-27 | — | — | US | claimed |
| US-20020082274-A1 | Preparation of sodium-hydrogen exchanger type-1 inhibitors | LAMBERT JOHN F (US) | 2002-06-27 | — | — | US | claimed |
| WO-2002044133-A1 | PREPARATION OF SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-06-06 | — | — | WO | claimed |
| EP-1101763-A2 | Method for preparing sodium-hydrogen exchanger type 1 inhibitor | Pfizer Products Inc. (US) | 2001-05-23 | — | — | EP | claimed |
| CN-1289326-A | N-[(substituted five-membered di-or thiaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER PROD INC (US) | 2001-03-28 | — | — | CN | claimed |
| EP-1056729-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2000-12-06 | — | — | EP | claimed |
| WO-1999043663-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 1999-09-02 | — | — | WO | claimed |
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| WO-2005079803-A1 | COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASES | PFIZER PRODUCTS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1056729-B1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | disclosed |
| CN-1289326-A | N-[(substituted five-membered di-or thiaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER PROD INC (US) | 2001-03-28 | — | — | CN | disclosed |
| EP-1056729-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043663-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119873-A1 | METHODS FOR PREPARING SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | NHERF1, SLC9A1, SLC9A2 | SLC9A1 2/4885SLC9A2 3/4885OPRM1 2537/4885 |
| US-20020082274-A1 | Preparation of sodium-hydrogen exchanger type-1 inhibitors | SLC9A1, NHERF1, SLC9A5 | SLC9A1 1/4885SLC9A2 5/4885OPRM1 1965/4885 |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | SLC9A1 5/4885SLC9A2 12/4885OPRM1 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.